KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Amortization - Intangibles (2019 - 2025)

Pacira BioSciences (PCRX) has 7 years of Amortization - Intangibles data on record, last reported at $14.3 million in Q4 2025.

  • For Q4 2025, Amortization - Intangibles changed 0.39% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $57.3 million, changed 0.06%, while the annual FY2025 figure was $57.3 million, 0.0% changed from the prior year.
  • Amortization - Intangibles reached $14.3 million in Q4 2025 per PCRX's latest filing, roughly flat from $14.3 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $14.3 million in Q4 2025 and bottomed at $2.0 million in Q1 2021.
  • Average Amortization - Intangibles over 5 years is $12.1 million, with a median of $14.3 million recorded in 2022.
  • Peak YoY movement for Amortization - Intangibles: soared 616.1% in 2022, then fell 0.24% in 2024.
  • A 5-year view of Amortization - Intangibles shows it stood at $7.7 million in 2021, then skyrocketed by 87.14% to $14.3 million in 2022, then changed by 0.0% to $14.3 million in 2023, then dropped by 0.24% to $14.3 million in 2024, then rose by 0.39% to $14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization - Intangibles were $14.3 million in Q4 2025, $14.3 million in Q3 2025, and $14.3 million in Q2 2025.